1. Home
  2. ETS vs APRE Comparison

ETS vs APRE Comparison

Compare ETS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ETS

Elite Express Holding Inc.

HOLD

Current Price

$1.09

Market Cap

12.0M

Sector

Industrials

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.61

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETS
APRE
Founded
2020
2006
Country
United States
United States
Employees
26
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
11.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ETS
APRE
Price
$1.09
$0.61
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
63.6K
59.6K
Earning Date
04-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.55
52 Week High
$1.21
$1.85

Technical Indicators

Market Signals
Indicator
ETS
APRE
Relative Strength Index (RSI) 66.00 34.09
Support Level $0.48 $0.57
Resistance Level N/A $0.83
Average True Range (ATR) 0.09 0.06
MACD 0.01 -0.01
Stochastic Oscillator 97.22 11.75

Price Performance

Historical Comparison
ETS
APRE

About ETS Elite Express Holding Inc.

Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: